Tissue Engineering Global Market Report 2024

The tissue engineering market size has grown rapidly in recent years. It will grow from $13.36 billion in 2023 to $15.38 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth observed in the historic period can be primarily attributed to several factors, including significant advancements in biomaterials, the expanding aging population demographic, a notable increase in the prevalence of chronic diseases, supportive regulatory measures for regenerative medicine practices, and a rising demand from patients for organ transplants. These elements collectively contributed to the growth and development within the field of tissue engineering and regenerative medicine.

The tissue engineering market size is expected to see rapid growth in the next few years. It will grow to $26.33 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. The anticipated growth in the forecast period can be attributed to several key factors, including the adoption of precision medicine approaches, a heightened emphasis on immunomodulation techniques, broader applications within orthopedic treatments, augmented funding and investment in the field, and a growing incidence of chronic diseases. These factors collectively drive the anticipated advancements within tissue engineering and regenerative medicine. Major trends expected during this period encompass the integration of nanotechnology into methodologies, the utilization of advanced 3D cell culture techniques, the development and utilization of organ-on-a-chip technology, the integration of artificial intelligence in research and applications, and the exploration of innovative cell sources. These trends are poised to shape and drive the evolution of tissue engineering and regenerative medicine practices in the forecasted period.

The anticipated increase in the prevalence of chronic diseases and trauma emergencies is poised to drive the growth of the tissue engineering market. Chronic diseases are characterized by enduring clinical conditions that persist for three months or longer, often requiring ongoing management without definitive cures. Conversely, trauma emergencies refer to sudden and severe physical injuries necessitating immediate medical attention, such as traumatic brain injuries. Healthcare professionals widely adopt tissue engineering for treating chronic disorders and trauma, employing various techniques such as autologous or allograft transplantation, xenotransplantation, and artificial substitutes. For example, a March 2021 report from Mary Ann Liebert, Inc. indicated that approximately 2% of the total U.S. population is affected by chronic wounds, while in 2020, the Centers for Disease Control and Prevention (CDC) recorded around 64,000 traumatic brain injuries in the United States, resulting in approximately 176 deaths daily due to TBI. This underscores the critical role of tissue engineering in addressing prevalent chronic diseases and trauma emergencies, driving the growth of the tissue engineering market.

The rising prevalence of cardiovascular disorders is expected to further contribute to the growth of the tissue engineering market. Cardiovascular disorders, also known as cardiovascular diseases (CVD), encompass various medical conditions affecting the heart and blood vessels. In tissue engineering, solutions are developed to repair and regenerate damaged cardiac and vascular tissues, offering promising treatment options. According to the World Health Organization in 2021, more than 15 million people aged 30 to 69 die annually from non-communicable diseases (NCDs), with cardiovascular disease being the most common, causing 17.9 million deaths each year. This prevalence, particularly in low- and middle-income countries, emphasizes the demand for effective solutions, further driving the growth of the tissue engineering market. The tissue engineering market's expansion is underscored by its role in addressing a spectrum of medical conditions, from chronic diseases to trauma emergencies and cardiovascular disorders.

Technological advancement stands out as a prominent trend gaining momentum in the tissue engineering market. Major companies within the industry are placing a significant focus on research and development to drive product innovations, providing enhanced solutions and solidifying their market positions. An example of this commitment is CELLINK, a U.S.-based company specializing in tissue engineering, which introduced its advanced bioprinter in March 2021. The BIO MDX Series, operating on 3D bioprinting technology, utilizes bio-inks and living cells to construct natural 3D tissue structures. This innovative technology comprises printheads, nanoliter and picoliter dispensing channels, and robotic integration, enabling precision bioprinting for high-throughput fabrication. The utilization of advanced bioprinting technologies reflects the industry's dedication to pushing the boundaries of tissue engineering for improved outcomes in cell-based technologies.

Major companies are strategically engaging in partnerships and collaborations with start-ups and mid-sized companies to expand their product and service offerings in the tissue engineering market. These collaborative efforts play a crucial role in broadening companies' product portfolios and extending their geographical reach. An illustrative instance is the collaboration agreement between Regen Lab, a Swiss-based medical technology company specializing in tissue engineering, Long Island University (LIU), and the Dassault Systèmes Group (3DS) in June 2023. Under this agreement, LIU and RegenLab USA join forces to establish an industrial innovation accelerator, a new center of excellence dedicated to regenerative medicine and tissue engineering. Such strategic collaborations enhance the capabilities and offerings of companies in the tissue engineering market, fostering innovation and growth. LIU, based in the U.S., and Dassault Systèmes Group, a French software corporation, are key partners in this initiative.

In October 2022, Geistlich Pharma, a US-based company specializing in bone, cartilage, and tissue regeneration, completed the acquisition of Lynch Biologics, LLC. The financial specifics of this acquisition were not disclosed. This strategic move serves to bolster Geistlich's existing regenerative product portfolio and augments its growth prospects within the field. Lynch Biologics, the acquired company, is also based in the US and is known for its focus on regenerative medicine and tissue engineering. They specialize in supplying advanced biotechnology products aimed at fostering healing and tissue regeneration.

Major companies operating in the tissue engineering market report are Medtronic plc, Zimmer Biomet, Allergan plc, Organogenesis Holdings Inc., Integra LifeSciences, Stryker Corporation, DePuy Synthes Companies, Acelity L.P. Inc., B. Braun Melsungen AG, RTI Surgical Inc., AbbVie Inc., Becton Dickinson and Company, Baxter International Inc., Osiris Therapeutics Inc., Organovo Inc., BioTime Inc., Bio Tissue Technologies, Vericel Corporation, Smith and Nephew, Acell Inc., Athersys Inc., Tissue Regenix Group plc, Xeltis AG, Prellis Biologics, Butterfly Network Inc., iThera Medical GmbH, Bit Bio, Be Biopharma Inc., The Takeda Pharmaceutical Company, Frequency Therapeutics, TELA Bio Inc., Orthocell Limited.

North America was the largest region in the tissue engineering market in 2023. Asia-Pacific is expected to be the fastest-growing region in the tissue engineering market during the forecast period. The regions covered in the tissue engineering market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tissue engineering market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key categories within tissue engineering encompass synthetic scaffold materials, biologically derived scaffold materials, and other methodologies. Synthetic scaffold materials are synthetic polymers composed of fibrous proteins that simulate an extracellular matrix, promoting favorable cellular responses and behaviors in tissue engineering applications. These materials find diverse applications across orthopedics and musculoskeletal treatments, neurology, cardiovascular procedures, skin and integumentary therapies, dental applications, among others. Various end-users including hospitals, clinics, and ambulatory facilities utilize these materials for their respective medical applications.

The tissue engineering market research report is one of a series of new reports that provides tissue engineering market statistics, including the tissue engineering industry global market size, regional shares, competitors with a tissue engineering market share, detailed tissue engineering market segments, market trends and opportunities, and any further data you may need to thrive in the tissue engineering industry. This tissue engineering market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.